{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"65"}],"units":"Participants"}],"description":"The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV.","groups":[{"description":"See detailed description or participant flow.","id":"OG000","title":"Phase II - Alemtuzumab and Combination Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Only participants who started Alemtuzumab were analyzed per study design. Specifically, one patient declined Alemtuzumab and was excluded from this analysis.","reportingStatus":"POSTED","timeFrame":"8 months","title":"Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)","type":"PRIMARY","unitOfMeasure":"participants"}